Setting and Meeting Your Return Goals

The Myth of “Returns” Everyone Believes

In boardrooms and pitch decks, “returns” is usually shorthand for money. But in 2025’s investment landscape, the currency of return is shifting—sometimes subtly, sometimes violently.

Returns are no longer just about your quarterly profit percentage. They are about time reclaimed, influence expanded, and relationships secured. Some of the savviest investors aren’t just asking, “How much will I make?”—they’re asking, “What will this buy me access to?”

The Quiet Repricing of Risk

There’s a private conversation happening between hedge fund managers, sovereign wealth executives, and elite family offices. It goes something like this:

“Traditional ROI is an outdated scoreboard. What matters now is resilience ROI.”

This mindset is pushing capital into less visible, high-control assets:

Private infrastructure deals in politically stable but underreported regions.
Media influence stakes to shape narratives without being a public-facing owner.
Strategic philanthropy as a backdoor to policy shaping.

These are returns you can’t plot neatly in Excel—but they may determine who actually holds power in ten years.

The Access Economy: Your New Benchmark

In certain investment circles, the question isn’t, “What’s the yield?” but “Who will I sit next to at dinner?”

An equity position in a boutique art fund might put you in a private gallery with the diplomat who controls your next permit.
Co-investing in a climate-tech startup might unlock a spot on a closed-door environmental policy roundtable.

The smartest money in the room understands that every dollar is a ticket—to influence, protection, or early intelligence.

The Gossip No Analyst Will Publish

A well-placed insider hinted that one global investment summit this year saw a coalition of three investors pool funds into a public company—not to drive profit, but to secure leverage in a regulatory negotiation. Officially, the move was about “growth potential.” Unofficially, it was about ensuring certain laws stayed favourable.

In another whispered case, a billionaire’s “underperforming” sports team investment became wildly profitable—not because of ticket sales, but because it gave them the perfect excuse to meet heads of state in VIP boxes.

Your Strategy for Return in 2025 and Beyond

Redefine your metrics. Include access, influence, and insulation in your ROI model.
Track closed-door events. The deals that secure the future are often invisible in public markets.
Factor in time and agility. Being able to exit or pivot without media scrutiny can be worth more than a fat dividend.

Why These Matter

Because money alone is no longer the measure of success—strategic positioning is.
Because the true value of an investment may be in who it introduces you to, not what it pays you.
Because ignoring these hidden return metrics risks leaving you rich in numbers but poor in power.

‍

The City Must Learn to Live With Water

The modern city has spent more than a century attempting to make water disappear. Rain falls onto roofs, roads and pavements. Gutters collect it. Drains capture it. Pipes bury it. Pumps move it. Rivers are channelled. Wetlands are filled. Coastlines are defended. The engineering objective has largely been straightforward: separate water from urban life as efficiently as possible. That model is reaching its limits. Around 600 million urban residents already live with significant annual flood hazard, according to the World Bank. Globally, 1.81 billion people live in flood-prone areas, while annual urban flood losses could approach $50 billion by 2050. Rapid urbanisation, ageing drainage infrastructure, land subsidence and changing rainfall patterns are interacting with the basic physical reality that cities have covered enormous portions of naturally absorbent ground with concrete and asphalt. Yet the consequential story is not simply that cities need bigger drains. A different philosophy of urban resilience is emerging: parks designed to flood temporarily; streets shaped to carry cloudbursts; wetlands restored as infrastructure; plazas capable of storing stormwater; permeable landscapes that absorb rainfall; buildings elevated or adapted to tolerate inundation; sensors that reveal water movement in real time; and neighbourhoods organised around the understanding that some water cannot — and perhaps should not — be engineered away. The World Bank increasingly describes effective urban flood management as an integration of grey infrastructure, green infrastructure, nature-based systems, planning, warning systems and institutional reform, rather than reliance on any single engineering intervention. The conceptual reversal is enormous. For generations, successful urbanisation meant controlling nature sufficiently to construct the city. The next generation of urbanism may require something more intelligent: designing the city so nature can still function inside it.

The Price of Money Is Becoming Political Again

For much of the post-financial-crisis era, wealthy economies became accustomed to an extraordinary condition: money was cheap. Governments could borrow heavily, companies could finance expansion at modest rates, asset prices could rise on abundant liquidity, and households learned to treat low-cost mortgages as something approaching economic normality. That world is disappearing fast. Across major economies, long-term government borrowing costs have climbed towards levels not seen for years or decades. On 17 August, the US 30-year Treasury yield reached roughly 5.31 per cent, its highest level since 2007. Japan’s 10-year government bond yield subsequently approached 2.95 per cent, a three-decade high, while German borrowing costs have risen to 15-year highs. The OECD describes the present combination of elevated financing requirements and elevated yields as exceptional compared with the previous two decades. Behind those numbers is a larger structural contest. Governments need capital for debt refinancing, defence, infrastructure, pensions, healthcare and climate resilience. Technology companies require extraordinary sums for artificial-intelligence infrastructure. Energy systems require grids, generation and storage. Businesses require investment. Families require mortgages and credit. These demands do not occupy separate universes. They ultimately encounter the same fundamental economic resource: capital. And when many powerful institutions want more of it simultaneously, the price of money stops being an obscure financial-market variable. It becomes a question of who gets financed, at what price, and at whose expense.

Cancer Vaccines Are Becoming Personal

For more than a century, the word vaccine has largely meant prevention: teach the immune system to recognise a threat before disease takes hold. Cancer is forcing medicine to reconsider that architecture. A new generation of experimental therapies is attempting something considerably more individual: sequence a patient’s tumour, identify mutations particular to that cancer, manufacture instructions corresponding to selected tumour-specific targets, and teach the patient’s immune system to recognise what belongs to the cancer growing inside that particular body. On 19 August, Moderna and Merck announced that their Phase III trial of the investigational personalised mRNA therapy intismeran autogene, used with Merck’s checkpoint inhibitor Keytruda after surgery for high-risk melanoma, achieved statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. The global trial enrolled 1,137 patients with resected stage IIB–IV melanoma. No new safety concerns were identified in the announcement. Full detailed Phase III results remain pending. The result matters because this is not simply another medicine administered to everyone carrying the same diagnosis. Intismeran is designed individually. Tumour and normal tissue are sequenced; mutations are analysed computationally; selected neoantigens — abnormal molecular features produced by the tumour — become the targets encoded into an mRNA therapy manufactured for that patient. Earlier Phase IIb evidence provides important context rather than a substitute for the unreleased Phase III detail. At five-year median follow-up, Moderna and Merck reported that intismeran plus Keytruda reduced the risk of recurrence or death by 49 per cent and distant metastasis or death by 59 per cent compared with Keytruda alone in that smaller study. The larger significance therefore extends beyond melanoma. Medicine has spent generations classifying disease so that patients with sufficiently similar conditions can receive sufficiently similar treatments. Personalised cancer vaccines suggest a different possibility: the diagnosis may identify the disease, while the tumour itself helps design the medicine. If that model succeeds across cancers, one of medicine’s great industrial achievements — standardisation — will begin coexisting with its apparent opposite: manufacturing treatment for one.